Application
BRF1 Antibody (Center) western blot analysis in Hela cell line lysates (35ug/lane).This demonstrates the BRF1 antibody detected the BRF1 protein (arrow).| Product Name | BRF1 Antibody (Center) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | BRF1; BRF; GTF3B; TAF3B2; TAF3C; Transcription factor IIIB 90 kDa subunit; B-related factor 1; TATA box-binding protein-associated factor, RNA polymerase III, subunit 2 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | BRF GTF3B TAF3B2 TAF3C |
|---|---|
| Alternative Names | BRF1 BRF GTF3B TAF3B2 TAF3C Transcription factor IIIB 90 kDa subunit B-related factor 1 TATA box-binding protein-associated factor RNA polymerase III subunit 2 |
| Molecular Weight(MW) | 73840 Da |
| Function | General activator of RNA polymerase which utilizes different TFIIIB complexes at structurally distinct promoters. The isoform 1 is involved in the transcription of tRNA, adenovirus VA1, 7SL and 5S RNA. Isoform 2 is required for transcription of the U6 promoter |
| Tissue Specificity | This BRF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 313-342 amino acids from the Central region of human BRF1. |
| Cellular Localization | Nucleus (By similarity). |
| Entrez Gene | 2972 |
|---|---|
| Nucleotide Accession | NP_663718.1 NP_001510.2 |
Application
BRF1 Antibody (Center) western blot analysis in Hela cell line lysates (35ug/lane).This demonstrates the BRF1 antibody detected the BRF1 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
